Early clinical evaluation and comparison with Priodax demonstrated the much denser gallbladder shadows found after ingestion of Telepaque in 3-gm. dosage and also showed a high incidence of unabsorbed contrast material in the colon. These findings pointed to the possibility that the 3-gm. dosage might be excessive, and it was suggested by others and concurred in by us that a thorough trial of a smaller dosage was indicated (1–6). Accordingly, a routine 2-gm. dosage was instituted at the University Hospital. Following the trial period for accumulation of data, this proved so satisfactory that it has been continued as standard cholecystographic procedure. A previous study at this institution (6) evaluated the side-effects of the 3-gm. dose of Telepaque in comparison with an equal dose of Priodax. Under identical conditions, cholecystographic subjects were interviewed by a physician as they passed through the gastrointestinal suite, and the side-effects of the 2-gm. dosage were tabulated. The contrast material was ingested exactly as in the previous study, i.e., following a fat-free meal the evening prior to examination. The incidence of side-effects as compared with the earlier Priodax and Telepaque (3-gm.) series is presented in Table I. The comparative figures show a small increase over the 3-gm. Telepaque group in absence of side-effects and a slight decrease in the two more frequent effects, mild diarrhea and mild dysuria, the reductions in these symptoms being in the neighborhood of 4 to 5 per cent. Thus it appears that the smaller 2-gm. dose enjoys an advantage in this respect when used as a routine procedure. The other chief concern in use of the reduced dosage is its effect on the density of the gallbladder shadow. A review of 500 examinations was carried out with the same standards employed in our previous studies (6), and gallbladder visualization was classified under the same headings: excellent, good, faint, or non-visualization, for each examination. The presence of stones was also recorded and it was noted whether they were radiolucent, radiopaque, or mixed. The incidence of residual contrast material in the colon was tabulated. Gallbladder visualization with 2-gm. dosage is compared with the previous study of 3-gm. dosage in Table II. While there appears to be a 13 per cent decrease in the “excellent” category, an increase of 9.2 per cent is noted in the “good” results. If the excellent and good classifications are combined and considered as “satisfactory” the 3-gm. dosage shows an advantage of 3.8 per cent over the 2-gm. dosage, S3 as compared to 79.2 per cent. This small decrease in diagnostic shadows with the lower dosage may be counterbalanced by the risk of obscuring stones by the dense shadows produced by 3 gm. Of the 500 patients receiving 2 gm., 487, or 97.4 per cent, showed residual contrast medium in the colon.
Read full abstract